TOXICOLOGICAL PROFILE FOR BARIUM AND COMPOUNDS ...

More documents

Recommendations

Info

A-2 APPENDIX A three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Table 2-1, 2-2, and 2-3, respectively). LSE figures are limited to the inhalation (LSE Figure 2-1) and oral (LSE Figure 2-2) routes. (2). Exposure Duration Three exposure periods: acute (14 days or less); intermediate (15 to 364 days); and chronic (365 days or more) are presented within each route of exposure. In this example, an inhalation study of intermediate duration exposure is reported. (3). Health Effect The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in the "System" column of the LSE table. (4). Key to Figure Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to define a NOAEL and a Less Serious LOAEL (also see the two "18r" data points in Figure 2-1). (5). Species The test species, whether animal or human, are identified in this column. (6). Exposure Freouency/Duration The duration of the study and the weekly and daily exposure regimen are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to [substance x] via inhalation for 13 weeks, 5 days per week, for 6 hours per day. (7). System This column further defines the systemic effects. These systems include: respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, one systemic effect (respiratory) was investigated in this study. (8). NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system which was used to derive an intermediate exposure, inhalation MKL of 0.005 ppm (see footnote 'c"). (9). LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest exposure level used in the study that caused a harmful health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with ncreasing dose. A brief description of the specific end point used to
A-3 APPENDIX A quantify the adverse effect accompanies the LOAEL. The “Less Serious" respiratory effect reported in key number 18 (hyperplasia) occurred at a LOAEL of 10 ppm. (10). Reference The complete reference citation is given in Chapter 8 of the profile. (11). CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiological studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses which did not cause a measurable increase in cancer. (12). Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "c" indicates the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm. LEGEND See LSE Figure 2-1 LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure levels for particular exposure duration. (13). Exposure Duration The same exposure periods appear as in the LSE table. In this example, health effects observed within the intermediate and chronic exposure periods are illustrated. (14). Health Effect These are the categories of health effects for which reliable quantitative data exist. The same health effects appear in the LSE table. (15). Levels of Exposure Exposure levels for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure levels are reported on the log scale "y" axis. Inhalation exposure is reported in mg/m 3 or ppm and oral exposure is reported in mg/kg/day. (16). NOAEL In this example, 18r NOAEL is the critical end point for which an intermediate inhalation exposure MRL is based. As you can see from the LSE figure key, the open-cir,cle symbol indicates a NOAEL for the test species (rat). The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table). (17). CEL Key number 38r is one of three studies for which Cancer Effect Levels (CELs) were derived. The diamond symbol refers to a CEL for the test species (rat). The number 38 corresponds to the entry in the LSE table.
Page 1 and 2:
TOXICOLOGICAL PROFILE FOR BARIUM AN
Page 3:
iii FOREWORD The Superfund Amendmen
Page 14 and 15:
2 1. PUBLIC HEALTH STATEMENT chlori
Page 16 and 17:
4 1. PUBLIC HEALTH STATEMENT irrita
Page 19 and 20:
7 2. HEALTH EFFECTS 2.1 INTRODUCTIO
Page 21 and 22:
9 2. HEALTH EFFECTS from any of the
Page 23 and 24:
11 2. HEALTH EFFECTS 2.2.1.5 Develo
Page 25:
13 2. HEALTH EFFECTS Mortality has
Page 34 and 35:
22 2. HEALTH EFFECTS either 0.071,
Page 36 and 37:
24 2. HEALTH EFFECTS plasma fibrino
Page 38 and 39:
26 2. HEALTH EFFECTS rats and mice
Page 40 and 41:
28 2. HEALTH EFFECTS barium/kg/day
Page 42 and 43:
30 2. HEALTH EFFECTS purulent disch
Page 44 and 45:
32 2. HEALTH EFFECTS Experiments in
Page 46 and 47:
34 2. HEALTH EFFECTS Animal studies
Page 48 and 49:
36 2. HEALTH EFFECTS may potentiall
Page 50 and 51:
38 2. HEALTH EFFECTS sulfate enema
Page 52 and 53:
40 2. HEALTH EFFECTS system were re
Page 54 and 55:
42 2. HEALTH EFFECTS microscopic le
Page 56 and 57:
44 2. HEALTH EFFECTS designed to te
Page 58 and 59:
46 2. HEALTH EFFECTS either appeara
Page 60 and 61:
48 2. HEALTH EFFECTS Barbiturates h
Page 63 and 64:
51 2. HEALTH EFFECTS Singh 1970; Di
Page 65 and 66:
53 2. HEALTH EFFECTS Reduced lifesp
Page 67 and 68:
55 2. HEALTH EFFECTS Developmental
Page 69 and 70:
57 2. HEALTH EFFECTS of barium, wel
Page 71:
59 3. CHEMICAL AND PHYSICAL INFORMA
Page 83 and 84:
71 4. PRODUCTION, IMPORT, USE, AND
Page 85:
73 5. POTENTIAL FOR HUMAN EXPOSURE
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 99 and 100:
Page 101: 89 5. POTENTIAL FOR HUMAN EXPOSURE
Page 105: 93 6. ANALYTICAL METHODS 6.2 ENVIRO
Page 109: 97 6. ANALYTICAL METHODS However, i
Page 117 and 118: 105 8. REFERENCES ACGIH. 1982. TLVs
Page 119 and 120: 107 8. REFERENCES *Boothe PN. James
Page 121 and 122: 109 8. REFERENCES Clary JJ, Tardiff
Page 123 and 124: 111 8. REFERENCES Douglas WW, Rubin
Page 125 and 126: 113 8. REFERENCES *EPA. 1984. Healt
Page 127 and 128: 115 8. REFERENCES *FSTRhC. 1988. Fe
Page 129 and 130: 117 8. REFERENCES *Hem JD. 1959. St
Page 131 and 132: 119 8. REFERENCES Kolpakov W. 1971.
Page 133 and 134: 121 8. REFERENCES *McCauley PT, Dou
Page 135 and 136: 123 8. REFERENCES NIOSH. 1987a. NIO
Page 137 and 138: 125 8. REFERENCES *Pierce FD, Brown
Page 139 and 140: 127 8. REFERENCES *Sax NI, Lewis RJ
Page 141 and 142: 129 8. REFERENCES Simmonds RJ, Jame
Page 143 and 144: 131 8. REFERENCES Syed IB, Hosain F
Page 145: 133 8. REFERENCES Weiss G, ed. 1986
Page 148 and 149: 136 9. GLOSSARY Immediately Dangero
Page 150 and 151: 138 9. GLOSSARY Short-Term Exposure
Page 154: A-4 APPENDIX A (18). Estimated Uppe
Page 158: A-8 APPENDIX A MRL users should be
show all

TOXICOLOGICAL PROFILE FOR BARIUM AND COMPOUNDS ...

Create successful ePaper yourself

Delete template?

Save as template?